Comparison between the AroCell TK 210 ELISA and TK1 enzyme activity assays

AroCell recently completed a comparison between their 210 ELISA with the ABCAM TK1 ELISA and the Gold-Standard Tritiated TK1 Activity Assay to confirm the diagnostic accuracy of each kit. The results found that the AroCell kit is an accurate assay for the determination of thymidine kinase 1.

Read the report here.

Eagle Biosciences offers the AroCell TK 210 ELISA as part of our product catalog:
TK 210 (Thymidine Kinase 1 (TK1)) ELISA Assay Kit

Contact us for more information about this or other enzyme activity assays.


Eagle Biosciences and AroCell are pleased to invite you to a
webinar on the application of the TK
210 (Thymidine Kinase 1) ELISA
in the study of malignancies.

There are many biomarkers of tumor mass, but few serum
biomarkers of tumor proliferation, a key indicator when making prognoses
and choosing and monitoring therapy.

The assay of serum Thymidine Kinase 1 with the AroCell TK 210
ELISA has the potential to be such a biomarker. There is no cost for
this event.


When: March
23, 2017 | 11 am to 11:30 am EDT


  • Staffan Eriksson, Professor in Medical and Physiological Chemistry, Swedish
    University of Agricultural Sciences
  • Martin
    , Business Development Manager at AroCell.

Key points of the presentation will be:

  • Thymidine
    kinase 1 (TK1) is a well-known proliferation biomarker but most
    current methods are based on enzyme activity methods and may
    underestimate serum TK1 levels, particularly in subjects with solid
  • The AroCell
    TK 210 ELISA adds value to studies with existing tumor biomarkers
  • Data will be
    presented on the value of the AroCell TK 210 ELISA in the study of a
    range of hematological and solid tumors.

Receive a white paper on the use of TK1 and the AroCell TK210 ELISA in studying solid tumors HERE



About AroCell

AroCell AB was founded in 2003. The company is located in Uppsala, Sweden and develops and commercializes tests that can be used in the prognosis, monitoring and follow-up of cancer.